Randomized trial uncovers clonal architecture and mutation patterns in metastatic colorectal cancer, highlighting implications for late-stage cancer evolution.
The evolutionary dynamics of cancer genomes at single-cell resolution under therapeutic pressure remain elusive. Hence, we perform whole-genome sequencing of 58 single-cell-derived tumoroids and 18 matched bulk tumors from six patients with metastatic colorectal cancer. High-resolution phylogenies reveal the clonal evolution of cancer with quantitative and qualitative profiling of therapy-associated mutations at the single-cell level. We uncover pronounced inter- and intra-patient heterogeneity in burden and spectrum of chemotherapy-induced mutations, with preferential enrichment in more proliferative lineages, highlighting differential mutagenic effects across co-existing cancer cell populations. Late-stage mutational trajectories uncover strikingly dynamic genomic alterations, including complex structural variants, extrachromosomal DNA amplifications, and LINE-1 retrotranspositions, often involving alterations in cancer driver genes. Together, we show the clonal architecture and mutational landscapes of advanced cancers under therapeutic pressure, providing an important foundation for future studies of late-stage cancer evolution under therapies. The evolutionary changes in cancer genomes under treatment are not fully understood. Here, whole-genome sequencing of 58 single-cell tumoroids and 18 matched bulk tumours from 6 metastatic colorectal cancer patients reveals clonal structures and mutation patterns under therapy.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: